The Methodist Hospital Research Institute
houstonmethodist.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
150
Active
61
Phase 3
4
Total enrollment
13,260
Pipeline matrix
Showing 40 of 57 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Intraosseous Vancomycin | — | — | — | 4 | |||
| Intravenous Vancomycin | — | — | — | — | 3 | ||
| Bevacizumab | — | — | — | — | 3 | ||
| Atezolizumab | — | — | — | — | 2 | ||
| Intervention - Intraosseous (IO) administration of vancomycin | — | — | — | — | — | 1 | |
| Control - Standard IV administration of vancomycin | — | — | — | — | — | 1 | |
| Intraosseous Morphine | — | — | — | — | — | 1 | |
| Envarsus XR | — | — | — | — | — | 1 | |
| L-NMMA | — | — | — | — | 3 | ||
| ADV/HSV-tk | — | — | — | — | — | 2 | |
| Trastuzumab | — | — | — | — | — | 2 | |
| Pertuzumab | — | — | — | — | — | 2 | |
| Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections | — | — | — | — | — | 1 | |
| Epidiolex | — | — | — | — | — | 1 | |
| Clazakizumab | — | — | — | — | — | 1 | |
| Brachytherapy | — | — | — | — | — | 1 | |
| Dexamethasone Sodium Phosphate Injection 20 mg | — | — | — | — | — | 1 | |
| Dexamethasone Sodium Phosphate Injection 4mg | — | — | — | — | — | 1 | |
| Regorafenib | — | — | — | — | — | 1 | |
| 5FU/LV | — | — | — | — | — | 1 | |
| Trifluridine-tipiracil | — | — | — | — | — | 1 | |
| Fulvestrant Run-In | — | — | — | — | — | 1 | |
| Venous ethanol | — | — | — | — | — | 1 | |
| Belumosudil 200 mg QD | — | — | — | — | — | 1 | |
| Fruquintinib Combined With Chemotherapy | — | — | — | — | — | 1 | |
| IL-2 | — | — | — | — | — | 1 | |
| Semaglutide Plus IL-2 | — | — | — | — | — | 1 | |
| IO Administration of Cefazolin | — | — | — | — | — | 1 | |
| IO Administration of Vancomycin | — | — | — | — | — | 1 | |
| IV Administration of Cefazolin | — | — | — | — | — | 1 | |
| IV Administration of Vancomycin | — | — | — | — | — | 1 | |
| Valganciclovir | — | — | — | — | — | 1 | |
| Lenvatinib | — | — | — | — | — | 1 | |
| Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office | — | — | — | — | — | 1 | |
| Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR | — | — | — | — | — | 1 | |
| Ocrelizumab | — | — | — | — | — | 1 | |
| Sasanlimab | — | — | — | — | — | 1 | |
| All-Trans Retinoic Acid (ATRA) Dose 0 | — | — | — | — | — | 1 | |
| All-Trans Retinoic Acid (ATRA) Dose -1 | — | — | — | — | — | 1 | |
| All-Trans Retinoic Acid (ATRA) Dose 1 | — | — | — | — | — | 1 |
17 more active programs hidden
Next readouts
- 2018-12
- 2020-12-31
- 2022-05-31
- 2024-07-15
- 2024-10-30
- 2025-07-31
- 2025-08-01
- 2025-10-01
- 2025-12
- 2025-12-01
Top conditions
- Prostatic Neoplasms8
- Breast Cancer7
- Carcinoma, Renal Cell6
- Neurogenic Bladder5
- Healthy4
- Overactive Bladder4
- Alzheimer Disease4
- Delirium3
Frequently asked questions about The Methodist Hospital Research Institute
- How many clinical trials does The Methodist Hospital Research Institute have on ClinicalTrials.gov?
- The Methodist Hospital Research Institute is listed as the lead sponsor on 150 clinical trials in ClinicalTrials.gov, 61 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The Methodist Hospital Research Institute's trials are in Phase 3?
- 4 of The Methodist Hospital Research Institute's trials are in Phase 3, spread across 57 active drug programs.
- What therapeutic areas does The Methodist Hospital Research Institute focus on?
- The Methodist Hospital Research Institute's most-studied conditions on ClinicalTrials.gov are Prostatic Neoplasms, Breast Cancer, Carcinoma, Renal Cell, Neurogenic Bladder, Healthy.
- When are The Methodist Hospital Research Institute's next clinical trial readouts?
- The Methodist Hospital Research Institute has 10 upcoming primary-completion readouts tracked here; the soonest is “HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer”, expected around 2018-12.